Today we have Juliette Audet with us. Juliette is a Partner at Forbion a multi-stage venture fund in Amsterdam and Munich backing biotech companies in Europe and North America to impact the future of medicine.

Forbion is investing out of 2 separate funds: Forbion Ventures Fund VI and Forbion Growth Opportunities Fund II, of €750M and €600M respectively, with a total of 3b EUR AUM and an established portfolio of 44 companies, with notable investment including NewAmsterdam Pharma, Gyroscope and Inflazome.

At Forbion, Juliette focuses on the Venture strategy, investing in biotech companies from pre-clinical stage to Phase 1b and led the investments in NewAmsterdam Pharma, Mestag and Dualyx amongst others.

Jump to the parts that matter most to you 👀
00:02:10 - Transitioning from Consulting to Pharma and Biotech
00:03:44 - Discipline and Resilience in Career
00:05:18 - Recognizing the Moment to Fold
00:07:17 - The Importance of Science and Interaction in Investments
00:08:50 - The Importance of Board Dynamics
00:10:25 - Board Composition and Power Dynamics
00:12:07 - Creating Consensus on the Board
00:13:37 - The Importance of Governance in Building an Effective Board
00:14:53 - Governance and relationship building with board members
00:16:35 - The Benefits of Virtual Board Meetings
00:18:21 - The Importance of Providing Value
00:20:30 - The Value of External Perspective in VC
00:22:21 - The Unique Nature of Biotech Companies
00:23:57 - Pharma's Need for External Acquisitions
00:25:47 - The Inflection Point in BioTech
00:27:16 - Slump in M&A Activity in Pharma-Biotech & the dawning opportunity
00:28:34 - The Development Process from Preclinical to Phase 3
00:29:58 - The Dynamic between CVCs and Institutional VCs in BioTech
00:33:14 - The Predictability of Biotech VC vs Traditional Venture
00:34:54 - Shoutout to Julie Grant from Canaan
00:36:33 - Balance and Fulfillment in VC
00:38:21 - Getting to know your LPs

EUVC #223 Juliette Audet, Partner at Forbion a €3 bn AUM leading BioTech firm in Europe.

EUVC